Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2161 to 2170 of 2733 total matches.

Conductive Keratoplasty (CK) for Presbyopia

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 2004  (Issue 1185)
been used to create monovision. THE PROCEDURE — CK improves near vision by inducing myopia (–1.00 to –2.00 ...
The ViewPoint CK System (Refractec) for conductive keratoplasty (CK), previously approved by the FDA as a device for treatment of hyperopia (farsightedness), was recently approved for treatment of presbyopia (age-associated loss of ability to view near objects).
Med Lett Drugs Ther. 2004 Jun 21;46(1185):49-50 |  Show IntroductionHide Introduction

COX-2 Alternatives and GI Protection

   
The Medical Letter on Drugs and Therapeutics • Nov 08, 2004  (Issue 1195)
-inflammatory, but has no GI toxicity. 1. What about celebrex? Med Lett Drugs Ther 2004; 46:87. 2. Drugs ...
With the removal of Vioxx from the market and concerns about cardiovascular toxicity with other selective COX-2 inhibitors, patients are looking for safe alternatives, and manufacturers of other drugs are looking for additional market share. The COX-2 inhibitors first became popular because they have less upper GI toxicity than older less selective NSAIDs, at least in the short term, in patients not taking aspirin.
Med Lett Drugs Ther. 2004 Nov 8;46(1195):91-2 |  Show IntroductionHide Introduction

In Brief: Mucinex

   
The Medical Letter on Drugs and Therapeutics • Feb 14, 2005  (Issue 1202)
” (GRAS) and is included in many prescription and over-the-counter cough remedies, 1 ...
Patients may be asking health care providers about the safety and effectiveness of Mucinex (Adams), which is being heavily advertised on television and elsewhere for treatment of respiratory congestion. These ads suggest that Mucinex is a new drug, when actually it is an extended-release formulation of guaifenesin, an old expectorant. Guaifenesin increases the volume of secretions in the respiratory tract, which facilitates removal of viscous mucus by coughing. Medical Letter consultants have not been impressed by its effectiveness. Guaifenesin is in the category of drugs - Generally...
Med Lett Drugs Ther. 2005 Feb 14;47(1202):16 |  Show IntroductionHide Introduction

Finasteride for Prevention of Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Jun 30, 2008  (Issue 1289)
prostate cancer. 1 THE DRUG — Approved by the FDA in 1992 for treatment of benign prostatic hyperplasia ...
Patients are asking physicians about an article on the front page of the June 15th New York Times, in which some prostate cancer experts were quoted as suggesting that men 55 and older might be well advised to take finasteride (Proscar, and others) to prevent prostate cancer.
Med Lett Drugs Ther. 2008 Jun 30;50(1289):49-50 |  Show IntroductionHide Introduction

In Brief: Biennial IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2009  (Issue 1315)
% with the drug and decreased by 2.1% with placebo. Among 357 osteopenic women >5 years after menopause, hip BMD ...
The FDA, which had previously approved intravenous (IV) administration of 5 mg of zoledronic acid (Reclast – Novartis) once a year for treatment of postmenopausal osteoporosis (Med Lett Drugs Ther 2007; 49:89), has now approved the same dose for use once every 2 years to prevent osteoporosis in postmenopausal women with osteopenia.Clinical Studies – In an unpublished study summarized in the package insert, 224 women with osteopenia ≤5 years after menopause were given an IV infusion of zoledronic acid 5 mg or placebo; 2 years later, total hip bone mineral density (BMD) had increased by...
Med Lett Drugs Ther. 2009 Jun 29;51(1315):49 |  Show IntroductionHide Introduction

Abuse-Deterrent Opioids

   
The Medical Letter on Drugs and Therapeutics • Jun 05, 2017  (Issue 1522)
last article on this subject,1 several new abuse-deterrent opioid formulations have been approved ...
Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Since our last article on this subject, several new abuse-deterrent opioid formulations have been approved by the FDA, including an oxycodone tablet formulation (Roxybond – Inspirion) that is the first immediate-release opioid product FDA-approved to include claims of abuse deterrence in its labeling. No opioid formulation prevents consumption of a large number of intact dosage units, the most common method of...
Med Lett Drugs Ther. 2017 Jun 5;59(1522):95-6 |  Show IntroductionHide Introduction

Maribavir (Livtencity) for Cytomegalovirus Infection (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
strains.1,2 MECHANISM OF ACTION — Maribavir inhibits CMV pUL97 kinase, resulting in inhibition of viral ...
Maribavir (Livtencity – Takeda), an oral cytomegalovirus (CMV) pUL97 kinase inhibitor, has been approved by the FDA for treatment of post-transplant CMV infection refractory to standard antiviral therapy in patients ≥12 years old who weigh at least 35 kg.
Med Lett Drugs Ther. 2022 Nov 28;64(1664):e193-4 |  Show IntroductionHide Introduction

Mobocertinib (Exkivity) for Non-Small Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
Exkivity: ex ki' vi tee Table 1. Pharmacology Class Kinase inhibitor Formulation 40 mg capsules Route ...
Mobocertinib (Exkivity – Takeda), an oral kinase inhibitor, has received accelerated approval from the FDA for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults whose disease has progressed on or after platinum-based chemotherapy. Accelerated approval was based on the overall response rate and duration of response. Mobocertinib is the second drug to become available in the US for this indication; the IV EGFR-MET bispecific antibody amivantamab (Rybrevant) was approved...
Med Lett Drugs Ther. 2022 Nov 28;64(1664):e197-8 |  Show IntroductionHide Introduction

AD-Detect — A Blood Test for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
) can improve their accuracy.1,2 In addition to AD-Detect, Quest offers a blood test for the ApoE ...
AD-Detect (Quest), a blood test to evaluate Alzheimer's disease risk, is being marketed directly to consumers. It has not been cleared or approved by the FDA (laboratory-developed tests like this one currently do not need FDA authorization to be marketed).
Med Lett Drugs Ther. 2023 Oct 30;65(1688):175-6   doi:10.58347/tml.2023.1688b |  Show IntroductionHide Introduction

In Brief: HPV Vaccine for Boys?

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2011  (Issue 1359)
% of anal cancer.1 Gardasil is highly effective in preventing infection with HPV types 6, 11, 16 and 18 ...
The FDA has approved a new indication for prevention of anal cancer and anal intraepithelial neoplasia in both sexes for the human papillomavirus (HPV) vaccine Gardasil (Merck). This vaccine is already FDA-approved for prevention of cervical cancer and genital warts in females 9-26 years old and for prevention of genital warts in males 9-26 years old. HPV types 6 and 11 cause about 90% of genital warts. Types 16 and 18 cause more than 70% of cervical cancer and about 80% of anal cancer.1 Gardasil is highly effective in preventing infection with HPV types 6, 11, 16 and 18 in both males and...
Med Lett Drugs Ther. 2011 Mar 7;53(1359):20 |  Show IntroductionHide Introduction